A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies.

LHC165 PDR001 TLR7 agonist advanced solid tumors

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 19 04 2024
revised: 18 06 2024
accepted: 18 06 2024
medline: 2 8 2024
pubmed: 2 8 2024
entrez: 1 8 2024
Statut: aheadofprint

Résumé

LHC165 is a Toll-like receptor (TLR)-7 agonist that generates an effective tumor antigen-specific T-cell adaptive immune response as well as durable antitumor responses. We aimed to evaluate the safety, tolerability, efficacy, dose-limiting toxicities, and pharmacokinetics (PK) of LHC165 single agent (SA) ± spartalizumab [PDR001; anti-programmed cell death protein 1 (PD-1)] in adult patients with advanced solid tumors. In this phase I/Ib, open-label, dose-escalation/expansion study, patients received LHC165 SA 100-600 μg biweekly through intratumoral (IT) injection and LHC165 600 μg biweekly + spartalizumab 400 mg Q4W through intravenous (IV) infusion. Forty-five patients were enrolled: 21 patients received LHC165 SA, and 24 patients received LHC165 + spartalizumab. The median duration of exposure was 8 weeks (range 2-129 weeks). No maximum tolerated dose was reached. Recommended dose expansion was established as LHC165 600 μg biweekly as SA and in combination with spartalizumab 400 mg Q4W. The most common drug-related adverse events (AEs) were pyrexia (22.2%), pruritus (13.3%), chills (11.1%), and asthenia (4.4%). The only serious AE (SAE) suspected to be related to the study drug was grade 3 pancreatitis (n = 1). Across all tumor types, overall response rate and disease control were 6.7% and 17.8%, respectively. Overall median progression-free survival (PFS) and immune-related PFS was 1.7 months. LHC165 serum PK demonstrated an initial rapid release followed by a slower release due to continued release of LHC165 from the injection site. LHC165 demonstrated acceptable safety and tolerability both as SA and in combination with spartalizumab, and evidence of limited antitumor activity was seen in adult patients with relapsed/refractory or metastatic solid tumors.

Sections du résumé

BACKGROUND BACKGROUND
LHC165 is a Toll-like receptor (TLR)-7 agonist that generates an effective tumor antigen-specific T-cell adaptive immune response as well as durable antitumor responses. We aimed to evaluate the safety, tolerability, efficacy, dose-limiting toxicities, and pharmacokinetics (PK) of LHC165 single agent (SA) ± spartalizumab [PDR001; anti-programmed cell death protein 1 (PD-1)] in adult patients with advanced solid tumors.
MATERIALS AND METHODS METHODS
In this phase I/Ib, open-label, dose-escalation/expansion study, patients received LHC165 SA 100-600 μg biweekly through intratumoral (IT) injection and LHC165 600 μg biweekly + spartalizumab 400 mg Q4W through intravenous (IV) infusion.
RESULTS RESULTS
Forty-five patients were enrolled: 21 patients received LHC165 SA, and 24 patients received LHC165 + spartalizumab. The median duration of exposure was 8 weeks (range 2-129 weeks). No maximum tolerated dose was reached. Recommended dose expansion was established as LHC165 600 μg biweekly as SA and in combination with spartalizumab 400 mg Q4W. The most common drug-related adverse events (AEs) were pyrexia (22.2%), pruritus (13.3%), chills (11.1%), and asthenia (4.4%). The only serious AE (SAE) suspected to be related to the study drug was grade 3 pancreatitis (n = 1). Across all tumor types, overall response rate and disease control were 6.7% and 17.8%, respectively. Overall median progression-free survival (PFS) and immune-related PFS was 1.7 months. LHC165 serum PK demonstrated an initial rapid release followed by a slower release due to continued release of LHC165 from the injection site.
CONCLUSIONS CONCLUSIONS
LHC165 demonstrated acceptable safety and tolerability both as SA and in combination with spartalizumab, and evidence of limited antitumor activity was seen in adult patients with relapsed/refractory or metastatic solid tumors.

Identifiants

pubmed: 39088985
pii: S2059-7029(24)01412-1
doi: 10.1016/j.esmoop.2024.103643
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103643

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

G Curigliano (G)

Istituto Europeo di Oncologia, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.

M M Jimenez (MM)

Hospital General Universitario Gregorio Maranon, Madrid, Spain.

T Shimizu (T)

National Cancer Center Hospital, Tokyo, Japan.

B Keam (B)

Seoul National University Hospital, Seoul, South Korea.

F Meric-Bernstam (F)

University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

A Rutten (A)

Sint-Augustinus Hospital, Antwerp, Belgium.

J Glaspy (J)

University of California, Los Angeles, California, USA.

P J Schuler (PJ)

Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.

N S Parikh (NS)

Biomedical Research, Novartis, East Hanover, New Jersey, USA.

M Ising (M)

Biomedical Research, Novartis, East Hanover, New Jersey, USA.

N Hassounah (N)

Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

J Wu (J)

Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

M Leyk (M)

Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

X Chen (X)

Biomedical Research, Novartis, East Hanover, New Jersey, USA.

H Burks (H)

Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

A Chaudhury (A)

Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

J Otero (J)

Biomedical Research, Novartis, East Hanover, New Jersey, USA.

E Garralda Cabanas (EG)

Vall d'Hebron Institute of Oncology (VHIO), Hospital Vall d'Hebron, Barcelona, Spain.

Classifications MeSH